RETINOL-BINDING PROTEIN 4 IN PATIENTS WITH DIABETES MELLITUS TYPE 2: RELATIONSHIP WITH THE LATEST BIOMARKERS / FACTORS CARDIOVASCULAR RISK

Authors

DOI:

https://doi.org/10.21856/j-PEP.2011.4.04

Keywords:

retinol-binding protein 4, type 2 diabetes mellitus, insulin resistance, markers of atherogenesis

Abstract

61 patients with type 2 diabetes mellitus were examined (disease duration 6.29 ± 0.67 years) overweight or obese, middle-aged, with hormonal and metabolic manifestations of insulin resistance (fasting hyperinsulinemia, elevated HOMA-IR indices and levels of free fatty acids, hypoadiponectinemia, hypertriglyceridemia). Significant increase in circulating levels of retinol-binding protein 4 (RVP4) was verified. with HOMA-IR indices, osteoprotegerin, progranulin, matrix metalloproteinase 9. The influence of sex on the severity of RVP4 increase and the associated pattern of macro- / microangiopathies were determined. The prospects of using circulating levels РВР4 as a quality are substantiated a new biomarker of cardiovascular risk.

References

Insulin action and age. European Group for the Study of Insulin Resistance (EGIR) [Text] / E. Ferrannini, S. Vichi, H. Beck-Nielsen [et al.] // Diabetes. — 1996. — Vol. 45. — P. 947–953.

DeFronzo, R. A. Insulin resistance, lipotoxity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 [Text] / R. A. DeFronzo // Diabetologia. — 2010. — Vol. 53. — P. 1270–1287.

Trayhurn, P. Adipokines: inflammation and the pleiotropic role of white adipose tissue [Text] / P. Trayhurn, I. S. Wood // Br. J. Nutr. — 2004. — Vol. 92. — P. 347–355.

Arner, P. Insulin resistance in type 2 diabetes: role of the adipokines [Text] / P. Arner // Curr. Mol. Med. — 2005. — Vol. 5. — P. 333–339.

Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes [Text] / Q. Yang, T. E. Graham, N. Mody [et al.] // Nature. — 2005. — Vol. 436. — P. 356–362.

Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation [Text] / Y. Fu, N. Luo, R. L. Klein [et al.] // J. Lipid. Res. — 2005. — Vol. 46. — P. 1369–1379.

Retinoids and retinoid-binding protein expression in rat adipocytes [Text] / C. Tsutsumi, M. Okuno, L. Tannous [et al.] // J. Biol. Chem. — 1992. — Vol. 267. — P. 1805–1810.

Newcomer, M. E. Plasma retinol binding protein: structure and function of the prototypic lipocalin [Text] / M. E. Newcomer, D. E. Ong // Biochim. Biophys. Acta. — 2000. — Vol. 1482. — P. 57–64.

Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects [Text] / T. E. Graham, Q. Yang, M. Bluher [et al.] // N. Engl. J. Med. — 2006. — Vol. 354. — P. 2552–2563.

Retinol-binding protein-4 levels and clinical features of type 2 diabetes patients [Text] / K. Takebayashi, M. Suetsugu, S. Wakabayashi [et al.] // J. Clin. Endocrinol. Metabol. — 2007. — Vol. 92. — P. 2712– 2719.

Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes [Text] / Y. M. Cho, B. S. Youn, H. Lee [et al.] // Diabetes Care. — 2006. — Vol. 29. — P. 2457–2461.

Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects [Text] / M. Broch, J. Vendrell, W. Ricart [et al.] // Diabetes Care. — 2007. — Vol. 30. — № 7. — P. 1802–1806.

Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease [Text] / M. von Eynatten, P. M. Lepper, D. Liu [et al.] // Diabetologia. — 2007. — Vol. 50. — P. 1930–1937.

High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans [Text] / N. Stefan, A. M. Hennige, H. Staiger [et al.] // Diabetes Care. — 2007. — Vol. 30. — № 5. —

P. 1173–1178.

Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass [Text] / J. Gomez-Ambrosi, A. Rodriguez, V. Catalan [et al.] // Clin. Endocrinol. — 2008. — Vol. 69. — P. 208–215.

Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes [Text] / S. Gavi, L. M. Stuart, P. Kelly [et al.] // J. Clin. Endocrinol. Metabol. — 2007. — Vol. 92. — № 5. — P. 1886 –1890.

Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects [Text] / D. G. Haider, K. Schindler, G. Prager [et al.] // J. Clin. Endocrinol. Metabol. — 2007. — Vol. 92. — № 3. — P. 1168–1171.

Retinol-binding protein 4 (RBP4) protein expression is increased in omental adipose tissue of severely obese patients [Text] / K. R. Kelly, S. R. Kashyap, V. B. O’Leary [et al.] // Obesity (Silver Spring). — 2010. — Vol. 18. — № 4. — P. 663–666.

Costantini, D. On the measurement of circulating antioxidant capacity and the nightmare of uric acid [Text] / D. Costantini // Methods in ecology and evolution. — 2011. — Vol. 2. — P. 321–325.

Schell, Th. Oxidative stress, implications in equine orthopedic disease, insulin resistance and a potential target for therapy [Text] / Th. Schell, C. Neatu // JAHYMA. — 2010. — Vol. 29. — № 1. — P. 11–15.

Richter, R. Determination of paraoxonase (pon 1) status requires more than genotyping [Text] / R. Richter, C. E. Furlong // Pharmacogenetics. — 1999. — Vol. 9. — P. 745–753.

Matthews, D. R. Homeostasis model assessement: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man [Text] / D. R. Matthews, J. P. Hosker, A. S. Rudenski // Diabetologia. — 1985. — Vol. 28. — P. 412–419.

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans [Text] / A. Katz, S. S. Nambi, K. Mather [et al.] // J. Clin. Endocrinol. Metabol. — 2000. — Vol. 85. — P. 2402–2410.

Kershaw, E. E. Adipose tissue as an endocrine organ [Text] / E. E. Kershaw, J. S. Flier // J. Clin. Endocrinol. Metabol. — 2004. — Vol. 89. — P. 2548– 2556.

Retinol binding protein 4: serum concentration, adipose secretion, and its relationship to obesity [Text] / R. Z. Yang, M. J. Lee, H. Hu [et al.] // Diabetes. — 2006. — Vol. 55. — Suppl. 1. — P. 87A.

Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus [Text] / J. S. Park, M. H. Cho, J. S. Nam [et al.] // EuroP. J. Endocrinol. — 2011. — Vol. 164. — № 1. — P. 69–74.

Diabetes Mellitus Enhances Vascular Matrix Metalloproteinase Activity Role of Oxidative Stress [Text] / S. Uemura, H. Matsushita, W. Li [et al.] // Circulation Research. — 2001. — Vol. 88. — P. 1291– 1298.

Intramuscular and liver triglycerides are increased in the elderly [Text] / M. G. Cree, B. R. Newcomer, C. S. Katsanos [et al.] // J. Clin. Endocrinol. Metabol. — 2004. — Vol. 89. — P. 3864–3871.

Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis [Text] / P. Collin-Osdoby, L. Rothe, F. Anderson [et al.] // J. Biol. Chem. — 2001. — Vol. 276. — P. 20659–20672.

Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells [Text] / L. C. Hofbauer, C. Shui, B. L. Riggs [et al.] // Biochem. Biophys. Res. Commun. — 2001. — Vol. 280. — P. 334–339.

Hofbauer, L. C. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases [Text] / L. C. Hofbauer, A. E. Heufelder // J. Clin. Endocrinol. Metabol. — 2000. — Vol. 85. — P. 2355–2363.

Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease [Text] / S. Jono, Y. Ikari, A. Shioi [et al.] // Circulation. — 2002. — Vol. 106. — P. 1192–1194.

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease [Text] / S. Kiechl, G. Schett, G. Wedding [et al.] // Circulation. — 2004. — Vol. 109. — P. 2175–2180.

Effects of vitamin A deficiency and repletion on rat insulin secretion in vivo and in vitro from isolated islets [Text] / B. S. Chertow, W. S. Blaner, N. G. Baranetsky [et al.] // J. Clin. Invest. — 1987. — Vol. 79. — P. 163–169.

Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling [Text] / E. Refai, N. Dekki, S. N. Yang [et al.] // Proc. Natl. Acad. Sci. — 2005. — Vol. 102. — P. 17020–17025.

Sivaprasadarao, A. The interaction of retinolbinding protein with its plasma-membrane receptor [Text] / A. Sivaprasadarao, J. B. Findlay // Biochem. J. — 1988. — Vol. 255. — P. 561–569.

Downloads

Published

2011-12-29

How to Cite

Gorshunska, M. (2011). RETINOL-BINDING PROTEIN 4 IN PATIENTS WITH DIABETES MELLITUS TYPE 2: RELATIONSHIP WITH THE LATEST BIOMARKERS / FACTORS CARDIOVASCULAR RISK. Problems of Endocrine Pathology, 38(4), 23-32. https://doi.org/10.21856/j-PEP.2011.4.04

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)

1 2 > >>